158 related articles for article (PubMed ID: 34397041)
1. Optimizing Positivity Thresholds for a Risk-Adapted Screening Strategy in Colorectal Cancer Screening.
Lu M; Wang L; Zhang Y; Liu C; Lu B; Du L; Liao X; Dong D; Wei D; Gao Y; Shi J; Ren J; Chen H; Dai M
Clin Transl Gastroenterol; 2021 Aug; 12(8):e00398. PubMed ID: 34397041
[TBL] [Abstract][Full Text] [Related]
2. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy comparison among high risk factors questionnaire and Asia-Pacific colorectal screening score and their combinations with fecal immunochemical test in screening advanced colorectal tumor].
Zhu N; Huang YQ; Song YM; Zhang SZ; Zheng S; Yuan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jul; 25(7):612-620. PubMed ID: 35844124
[No Abstract] [Full Text] [Related]
4. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis.
Zhong GC; Sun WP; Wan L; Hu JJ; Hao FB
Gastrointest Endosc; 2020 Mar; 91(3):684-697.e15. PubMed ID: 31790657
[TBL] [Abstract][Full Text] [Related]
6. Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk-Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial (TARGET-C).
Chen H; Lu M; Liu C; Zou S; Du L; Liao X; Dong D; Wei D; Gao Y; Zhu C; Zhu L; Zheng W; Xiao H; Kong Y; Yin H; Zhou H; Ying R; Wang B; Zhang J; Zhang X; Zhang Q; Zhang X; Zhang Y; Wang H; Guo L; Liu L; Ren J; Shi J; Li N; Miao X; Brenner H; Dai M
Am J Gastroenterol; 2020 Aug; 115(8):1264-1274. PubMed ID: 32282342
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Economic Impact of Tailoring Screening to Predicted Colorectal Cancer Risk: A Decision Analytic Modeling Study.
Ladabaum U; Mannalithara A; Mitani A; Desai M
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):318-328. PubMed ID: 31796524
[TBL] [Abstract][Full Text] [Related]
8. A combination of clinical risk stratification and fecal immunochemical test is useful for identifying persons with high priority of early colonoscopy.
Jung YS; Park CH; Kim NH; Park JH; Park DI; Sohn CI
Dig Liver Dis; 2018 Mar; 50(3):254-259. PubMed ID: 29198569
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score.
Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T
J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-Adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C).
Chen H; Shi J; Lu M; Li Y; Du L; Liao X; Wei D; Dong D; Gao Y; Zhu C; Ying R; Zheng W; Yan S; Xiao H; Zhang J; Kong Y; Li F; Zou S; Liu C; Wang H; Zhang Y; Lu B; Luo C; Cai J; Tian J; Miao X; Ding K; Brenner H; Dai M
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):808-818. PubMed ID: 35964896
[TBL] [Abstract][Full Text] [Related]
11. Demand for Colonoscopy in Colorectal Cancer Screening Using a Quantitative Fecal Immunochemical Test and Age/Sex-Specific Thresholds for Test Positivity.
Chen SL; Hsu CY; Yen AM; Young GP; Chiu SY; Fann JC; Lee YC; Chiu HM; Chiou ST; Chen HH
Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):704-709. PubMed ID: 29593012
[No Abstract] [Full Text] [Related]
12. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
[TBL] [Abstract][Full Text] [Related]
13. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
15. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
[TBL] [Abstract][Full Text] [Related]
17. Fecal occult blood testing when colonoscopy capacity is limited.
Wilschut JA; Habbema JD; van Leerdam ME; Hol L; Lansdorp-Vogelaar I; Kuipers EJ; van Ballegooijen M
J Natl Cancer Inst; 2011 Dec; 103(23):1741-51. PubMed ID: 22076285
[TBL] [Abstract][Full Text] [Related]
18. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
[TBL] [Abstract][Full Text] [Related]
19. The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis.
Thomas C; Mandrik O; Saunders CL; Thompson D; Whyte S; Griffin S; Usher-Smith JA
Cancer Prev Res (Phila); 2021 Aug; 14(8):811-822. PubMed ID: 34039685
[TBL] [Abstract][Full Text] [Related]
20. Identifying the optimal strategy for screening of advanced colorectal neoplasia.
Jung YS; Park CH; Kim NH; Park JH; Park DI; Sohn CI
J Gastroenterol Hepatol; 2017 May; 32(5):1003-1010. PubMed ID: 28449340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
